COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
On Thursday, Novavax Inc (NASDAQ:NVAX) reported second-quarter 2024 sales of $415 million, compared to $424 million a year, missing the consensus of $458.6 million.
周四，诺瓦瓦克斯医药（NASDAQ:NVAX）报告2024年第二季度销售收入为41500万美元，而去年同期为42400万美元，未达到45860万美元的共识。
Second quarter 2024 licensing, royalties, and other revenue include $391 million associated with the $500 million upfront payment received under the Sanofi SA (NASDAQ:SNY) agreement.
2024年第二季度的许可、版税和其他收入中，包括与赛诺菲安万特（NASDAQ:SNY）协议下收到的5000万美元预付款有关的39100万美元。
The COVID-19 vaccine maker reported EPS of $0.99, up from $0.58 a year ago, but it missed the consensus of $1.64.
这家COVID-19疫苗制造商报告的每股收益为0.99美元，高于去年同期的0.58美元，但未达到1.64美元的共识。
Net income for the second quarter of 2024 was $162 million, compared to a net income of $58 million in the same period in 2023.
2024年第二季度的净收入为1.62亿美元，而去年同期为5800万美元。
Also Read: Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern.
此外阅读：诺瓦瓦克斯COVID-19疫苗有所喘息，与赛诺菲签订了亿万美元的协议，消除了其业绩下行的疑虑。
"This is an exciting time for Novavax, and we have been keenly focused on evolving our operating model to leverage our key drivers of value," said John Jacobs, President and CEO.
“这是诺瓦瓦克斯令人兴奋的时刻，我们一直专注于演变我们的运营模式，以利用我们的关键价值驱动器，”总裁兼CEO约翰·雅各布斯表示。
"We intend to drive future value for the business through not only the Sanofi partnership but also through our late-stage combination and influenza assets. We plan to unveil a new and expanded clinical pipeline by the end of this year and leverage both the pipeline and our proven technology to drive additional partnerships and deals and to ultimately drive significant, long-term value for our shareholders."
“我们打算通过不仅赛诺菲合作伙伴关系，而且还通过我们的晚期组合和流感资产推动未来的价值增长。我们计划到今年年底之前推出新的和扩大的临床流水线，并利用流水线和我们已证明的技术，推动额外的合作伙伴关系和交易，并最终为我们的股东创造重大的、长期的价值。”
Guidance: Novavax expects 2024 revenue of $700 million – $800 million, including revenue recognition of Sanofi Payment, compared to the consensus of $936.38 million.
预测：诺瓦瓦克斯预计2024年收入为7亿美元-8亿美元，包括赛诺菲支付的收入确认，而共识为9363.8万美元。
Earlier, the company expected sales of $970 million – $1.17 billion in combined revenue and Sanofi agreement payment.
此前，该公司预计在2024年实现销售收入和赛诺菲协议付款的总额为9700万美元-11.7亿美元。
The company expects 2024 product sales of $275 million – $375 million, reflecting approximately $100 million in Advance Purchase Agreements (APA) dose deliveries in 1H 2024 and $175 million to $275 million of commercial market sales expected in 2H 2024.
该公司预计2024年产品销售额为2.75亿美元-3.75亿美元，其中包括1H 2024的约1亿美元的预购购买协议（APA）剂量交付以及2H 2024预计的1.75亿美元至2.75亿美元的商业市场销售额。
Price Action: NVAX stock is up 6.26% at $11.38 at the last check on Thursday.
NVAX股票周四最后一次查看涨了6.26%，至11.38美元。
- Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September.
- 诺瓦瓦克斯股票盘前上涨，公司计划在9月之前交付COVID-19疫苗。
Photo via Shutterstock
图片来自shutterstock。